Navigation Links
Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting
Date:12/10/2007

ivity during treatment with the combination.

In summary, these results appear to support and form the basis of testing the combination therapy of MGCD0103 and Vidaza in a larger randomized three-arm study which is currently being planned by the partners.

About MGCD0103

MGCD0103 is an orally-administered, isotype-selective HDAC inhibitor. The compound is currently in three Phase I/II clinical trials, in combination with Vidaza(R) for hematological malignances and with Gemzar(R) and Taxotere(R) in solid tumors; and in four Phase II monotherapy clinical trials in hematological malignancies.

About Vidaza

In May 2004, Vidaza became the first drug approved by the FDA for the treatment of patients with Myelodysplastic Syndromes (MDS). The FDA approved Vidaza, the first in a new class of drugs called demethylation agents, for treatment of all five MDS subtypes. These subtypes include: refractory anemia (RA) or refractory anemia with ringed sideroblasts (RARS) if accompanied by neutropenia or thrombocytopenia or requiring transfusions; refractory anemia with excess blasts (RAEB), refractory anemia with excess blasts in transformation (RAEB-T), and chronic myelomonocytic leukemia (CMMoL).

Vidaza is believed to exert its antineoplastic effects by causing hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in the bone marrow. The concentration of Vidaza required for maximum inhibition of DNA methylation in vitro does not cause major suppression of DNA synthesis. Hypomethylation may restore normal function to genes that are critical for differentiation and proliferation. The cytotoxic effects of Vidaza cause the death of rapidly dividing cells, including cancer cells that are no longer responsive to normal growth control mechanisms. Non- proliferating cells are relatively insensitive to Vidaza. Vidaza was approved for IV administration in January 2007.

About Epigenetic Therapy

DNA methylation and
'/>"/>

SOURCE Pharmion Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine news :

1. Pharmion and GPC Biotech Announce Results of Overall Survival Analysis From the Satraplatin Pivotal Phase 3 Trial
2. Pharmion to Present Clinical Data on Key Hematology Products at American Society of Hematology (ASH) Annual Meeting
3. Pharmion and Methylgene Report Favorable Results for Phase 2 MGCD0103 Single- Agent Studies in Relapsed or Refractory Lymphomas at the 49th American Society of Hematology (ASH) Meeting
4. AtriCure to Present at Thomas Weisel Partners 2007 Healthcare Conference
5. Matrixx Initiatives, Inc. to Present at the Roth Capital Partners 2007 New York Conference
6. BD to Present at the Bear Stearns 20th Annual Healthcare Conference
7. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
8. Omnicell to Present at Thomas Weisel Healthcare Conference 2007
9. AtriCure to Present at Roth Capital Partners 2007 New York Conference
10. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
11. MDS to Present at Thomas Weisel Partners Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Computer Resources of America, Inc. (CRA), an ... City, has been awarded the contract to rewire the ... large global bank. The bank is a global leader ... of CRA said, “Being awarded this contract with our ... what has already been a successful and deep relationship. ...
(Date:7/30/2014)... According to the Critical Bench Program 2.0 Pdf review ... for men who want to discover how to increase their ... within a few months. Inside this book, learners will discover ... and avoid the aches and pains. , Vkool reveals in ... learners the reason why stretching and warming up is so ...
(Date:7/30/2014)... 30, 2014 pMD, the leading ... launched an Observation Result (ORU) interface to streamline ... cardiology customers are using the ORU interface to ... test interpretations for electrocardiograms, echocardiograms, and stress tests. ... hospital, the cardiology system produces electronic data for ...
(Date:7/29/2014)... VisitandCare.com today announced that several ... the company’s exclusive network to help couples struggling with ... — as top fertility clinics in Spain, Switzerland, Greece, ... and successful IVF treatments. , The exclusive selection of ... by professionals at VisitandCare.com. The goal is to connect ...
(Date:7/29/2014)... 2014 Phytceramides are a natural anti-aging tool for ... new book. , Today is the last day to nab a ... Best . The book is also sold in hard copy. , ... that Phytoceramides were so new and very unknown in ... book now," says Kathy Heshelow, founder of Sublime Beauty®. "It is ...
Breaking Medicine News(10 mins):Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 2Health News:The Critical Bench Program 2.0 Pdf Review Exposes Mike Westerdal's Guide for Increasing Bench Press – Vkool.com 3Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 2Health News:pMD Automates Cardiology Charge Capture: Low-Reimbursement Services Become Profitable 3Health News:Top European Fertility Clinics Join VisitandCare.com 2Health News:Top European Fertility Clinics Join VisitandCare.com 3Health News:Top European Fertility Clinics Join VisitandCare.com 4Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 2Health News:Last Day New Book Is Available at No Cost: Phytoceramides, Anti Aging At Its Best by Sublime Beauty Founder® Kathy Heshelow 3
... Services, Treatment and Prevention Available--MINNEAPOLIS, April 29 ... health care centers in the United States, is ... flu (H1N1) and provide rapid testing services, treatment ... medically appropriate. MinuteClinic is coordinating with local ...
... 29 Grupo Aeroportuario del Sureste, S.A.B. de C.V. ... first privatized airport group in Mexico and operator of Cancun ... today that on April 26, 2009 the Mexican Secretary of ... in Mexico. On April 28, 2009 the World Health Organization ...
... BOTHELL, Wash., April 29 SCOLR Pharma, Inc. (NYSE Alternext ... financial results on Friday, May 1, 2009, at 8:30 a.m. ... Pharma, will host the conference call at 11:30 a.m. Eastern, ... other interested parties may participate in the conference call by ...
... Survey finds many cities have dangerously high levels of pollution ... of the nation,s population, 186.1 million people to be exact, ... air pollution, new research shows. , "Six out of ten ... the emergency room, to shape how kids, lungs develop and ...
... 2009 Relationships are difficult and most of us probably ... when discussing stressful issues, like home finances, is an impossible ... take the "edge" off these discussions? The biology of ... research on social cognition conducted in animals is now informing ...
... Michigan physicians are the first in the nation ... through a new partnership announced today by the American ... with Compuware,s Covisint subsidiary. This partnership builds on ... the AMA announced its agreement with Covisint to develop ...
Cached Medicine News:Health News:MinuteClinic is Educating Consumers About Swine Flu 2Health News:MinuteClinic is Educating Consumers About Swine Flu 3Health News:SCOLR Pharma, Inc. Schedules First Quarter 2009 Financial Results Conference Call for May 1, 2009 at 11:30 A.M. Eastern 2Health News:More Than Half of Americans Living with Dirty Air 2Health News:More Than Half of Americans Living with Dirty Air 3Health News:Oxytocin: Love potion #1? 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 2Health News:Michigan Physicians Gain From New AMA and MSMS Partnership to Improve Physician Practice Efficiency 3
(Date:7/29/2014)... NEW YORK , July 29, 2014 /PRNewswire-iReach/ ... on the basis of products, methods, applications, end ... register highest growth in the microbial identification market. ... in consumable costs (per test) and the time ... accuracy and continuous technological advancements. Furthermore, genotypic methods ...
(Date:7/29/2014)... July 29, 2014  Express Scripts Holding Company (Nasdaq: ... income attributable to Express Scripts stockholders of $515.2 million, ... share, as detailed in Table 4, was $1.23 for ... well positioned to serve our clients with scale, alignment and ... improve the health outcomes of our members," stated George Paz, ...
(Date:7/29/2014)... N.J. , July 29, 2014 Regado ... company focused on the Phase 3 clinical development of ... controllable antithrombotic drug system, today announced that it will ... Tuesday, Aug. 12, 2014, at 8:30 a.m. EDT to ... highlights. Interested participants and investors may access ...
Breaking Medicine Technology:Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 2Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 3Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 4Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 5Microbial Identification Market Growing at 5.9% CAGR to 2019: Global Forecast in New Research Report Available at ReportsnReports.com 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 2Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 3Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 4Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 5Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 6Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 7Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 8Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 9Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 10Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 11Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 12Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 13Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 14Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 15Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 16Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 17Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 18Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 19Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 20Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 21Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 22Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 23Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 24Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 25Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 26Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 27Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 28Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 29Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 30Express Scripts Announces 2nd Quarter Results; Narrows 2014 Guidance Range; Maintains Mid-Point 31
... for Healthcare ... Professionals, VOORHEES, ... that causes disease with a wide spectrum of,severity, ranging from mild ... to 20% of patients who develop an initial,case of CDI.(1) These ...
... Israel, July 1 Applisonix LTD (TASE:,APLS), a ... market, announced today that the test conducted using ... average hair,reduction of 38%, which positions its efficacy ... Applisonix, co-CEOs, Mr. Alon Goren and Mr. Uri ...
Cached Medicine Technology:Current Concepts in Clostridium difficile Infection: A Focus on Recurrent Disease 2Applisonix Announces Breakthrough in Ultrasound Technology for Hair Removal - Average Hair Reduction of 38% Following Initial Treatment 2
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
For the qualitative detection of single and multiple drugs and drug metabolites in human urine...
Escherichia coli - For the qualitative detection of Escherichia coli 0157 and 0157:H7 in food products. Accessories BinaxNOW EH E.coli 0157 & 0157:H7 Control Swab Pack (510-000), BinaxNow E.coli...
... qualitative differential detection of ... and an antigen that is ... of malaria:plasmodium falciparum (P.f), plasmodium ... and Plasmodium malariae (P.m) in ...
Medicine Products: